NIM
ALNY icon

NEOS Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

NEOS Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Buy
78,274
+9,401
+14% +$2.84M 0.09% 168
2026
Q1 		$22.8M Buy
68,873
+28,172
+69% +$9.59M 0.12% 139
2025
Q4 		$16.2M Buy
40,701
+38,138
+1,488% +$16.9M 0.09% 172
2025
Q3 		$1.17M Sell
2,563
-2,738
-52% -$1.11M 0.01% 497
2025
Q2 		$1.73M Sell
5,301
-1,174
-18% -$325K 0.02% 397
2025
Q1 		$1.75M Sell
6,475
-9,848
-60% -$2.53M 0.03% 349
2024
Q4 		$3.84M Sell
16,323
-1,853
-10% -$487K 0.09% 203
2024
Q3 		$5M Buy
18,176
+531
+3% +$138K 0.15% 126
2024
Q2 		$4.29M Buy
17,645
+6,276
+55% +$991K 0.18% 110
2024
Q1 		$1.7M Buy
11,369
+8,380
+280% +$1.4M 0.11% 186
2023
Q4 		$572K Buy
+2,989
New +$509K 0.05% 259

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NEOS Investment Management's ALNY Position: Q2 2026 in Review

NEOS Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 14% in Q2 2026, buying an estimated $2.84M and bringing the position to 78,274 shares worth $23.6M. The position accounts for 0.09% of the portfolio, ranked #168.

NEOS Investment Management first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • NEOS Investment Management held 78,274 shares of Alnylam Pharmaceuticals worth $23.6M as of Q2 2026.
  • NEOS Investment Management bought 9,401 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.84M.
  • Alnylam Pharmaceuticals made up 0.09% of NEOS Investment Management's portfolio in Q2 2026, its #168 holding.
  • NEOS Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on NEOS Investment Management's 13F filing for Q2 2026, filed 11 Aug 2026.